128 related articles for article (PubMed ID: 32986721)
1. Locally invasive, castrate-resistant prostate cancer in a Pten/Trp53 double knockout mouse model of prostate cancer monitored with non-invasive bioluminescent imaging.
Yong C; Moose DL; Bannick N; Gutierrez WR; Vanneste M; Svensson R; Breheny P; Brown JA; Dodd RD; Cohen MB; Henry MD
PLoS One; 2020; 15(9):e0232807. PubMed ID: 32986721
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.
Couto SS; Cao M; Duarte PC; Banach-Petrosky W; Wang S; Romanienko P; Wu H; Cardiff RD; Abate-Shen C; Cunha GR
Differentiation; 2009 Jan; 77(1):103-11. PubMed ID: 19281769
[TBL] [Abstract][Full Text] [Related]
3. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
4. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
5. Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.
Hafeez BB; Fischer JW; Singh A; Zhong W; Mustafa A; Meske L; Sheikhani MO; Verma AK
Cancer Prev Res (Phila); 2015 May; 8(5):375-86. PubMed ID: 25627799
[TBL] [Abstract][Full Text] [Related]
6. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice.
Takahara K; Ibuki N; Ghaffari M; Tearle H; Ong CJ; Azuma H; Gleave ME; Pollak M; Cox ME
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):239-47. PubMed ID: 23689346
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.
Shi M; Whorton AE; Sekulovski N; Paquet M; MacLean JA; Song Y; Van Dyke T; Hayashi K
Biol Reprod; 2020 Apr; 102(5):1055-1064. PubMed ID: 31930396
[TBL] [Abstract][Full Text] [Related]
8. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
9. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
11. Atg7 cooperates with Pten loss to drive prostate cancer tumor growth.
Santanam U; Banach-Petrosky W; Abate-Shen C; Shen MM; White E; DiPaola RS
Genes Dev; 2016 Feb; 30(4):399-407. PubMed ID: 26883359
[TBL] [Abstract][Full Text] [Related]
12. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
13. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
[TBL] [Abstract][Full Text] [Related]
14. Global deletion of Trp53 reverts ovarian tumor phenotype of the germ cell-deficient white spotting variant (Wv) mice.
Cai KQ; Wang Y; Smith ER; Smedberg JL; Yang DH; Yang WL; Xu XX
Neoplasia; 2015 Jan; 17(1):89-100. PubMed ID: 25622902
[TBL] [Abstract][Full Text] [Related]
15. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.
Svensson RU; Haverkamp JM; Thedens DR; Cohen MB; Ratliff TL; Henry MD
Am J Pathol; 2011 Jul; 179(1):502-12. PubMed ID: 21703427
[TBL] [Abstract][Full Text] [Related]
16. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.
Liao CP; Zhong C; Saribekyan G; Bading J; Park R; Conti PS; Moats R; Berns A; Shi W; Zhou Z; Nikitin AY; Roy-Burman P
Cancer Res; 2007 Aug; 67(15):7525-33. PubMed ID: 17671224
[TBL] [Abstract][Full Text] [Related]
17. Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival.
Mullany LK; Liu Z; King ER; Wong KK; Richards JS
Endocrinology; 2012 Apr; 153(4):1638-48. PubMed ID: 22396451
[TBL] [Abstract][Full Text] [Related]
18. Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome.
Cho H; Herzka T; Stahlhut C; Watrud K; Robinson BD; Trotman LC
Methods; 2015 May; 77-78():197-204. PubMed ID: 25592467
[TBL] [Abstract][Full Text] [Related]
19. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.
Martin P; Liu YN; Pierce R; Abou-Kheir W; Casey O; Seng V; Camacho D; Simpson RM; Kelly K
Am J Pathol; 2011 Jul; 179(1):422-35. PubMed ID: 21703421
[TBL] [Abstract][Full Text] [Related]
20. Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.
Liang M; Adisetiyo H; Li X; Liu R; Gill P; Roy-Burman P; Jones JO; Mulholland DJ
PLoS One; 2015; 10(7):e0131232. PubMed ID: 26196517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
